CIBC Asset Management Inc Has $4.27 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

CIBC Asset Management Inc raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 22.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 136,704 shares of the company’s stock after buying an additional 25,153 shares during the period. CIBC Asset Management Inc’s holdings in Teva Pharmaceutical Industries were worth $4,267,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in TEVA. Allworth Financial LP lifted its stake in shares of Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares in the last quarter. Grove Bank & Trust lifted its stake in shares of Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after buying an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares in the last quarter. Global Retirement Partners LLC lifted its stake in shares of Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after buying an additional 292 shares in the last quarter. Finally, 1620 Investment Advisors Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 1,823.2% in the fourth quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock valued at $49,000 after buying an additional 1,495 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Mark Sabag sold 144,180 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at $2,825,792.40. This trade represents a 64.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the transaction, the executive vice president directly owned 63,647 shares in the company, valued at $2,247,375.57. The trade was a 25.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 421,470 shares of company stock valued at $14,570,945 over the last three months. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported new real-world survey data showing AUSTEDO and AUSTEDO XR improved quality-of-life measures for Huntington’s disease chorea patients and reduced caregiver strain, supporting the outlook for one of its key branded medicines. Article Title
• Positive Sentiment: Teva expanded its European biosimilars business with the launch of AHZANTIVE, strengthening its growth strategy and broadening its presence in ophthalmology. Article Title
• Neutral Sentiment: Industry coverage highlighted Teva as a generic-drug stock to watch as biosimilars, complex generics and specialty drugs become increasingly important growth drivers. Article Title

Teva Pharmaceutical Industries Stock Down 0.6%

TEVA opened at $34.21 on Friday. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The company’s 50-day moving average is $32.82 and its 200 day moving average is $31.63. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The firm has a market capitalization of $39.34 billion, a P/E ratio of 25.72, a PEG ratio of 3.49 and a beta of 0.84.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion for the quarter. Research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on TEVA shares. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. The Goldman Sachs Group raised their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Piper Sandler reissued an “overweight” rating and set a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.